MARIA MITZI BRENTANI

(Fonte: Lattes)
Índice h a partir de 2011
17
Lattes
ResearcherID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Radiologia, Faculdade de Medicina - Docente
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/05 - Laboratório de Poluição Atmosférica Experimental, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Assunto: Pathology ×

Resultados de Busca

Agora exibindo 1 - 5 de 5
  • conferenceObject
    Claudin 4 and 7 Expression Is Not Correlated to Triple Negative Phenotype in Invasive NOS Breast Carcinomas: A Wide Series Assessed by Immunohistochemistry
    (2014) LOGULLO, A. F.; STIEPCICH, M. A.; NONOGAKI, S.; MALAGOLI, R.; BRENTANI, M. M.; PASINI, F. S.; SOARES, F. A.
  • conferenceObject
    Can neoadjuvant chemotherapy change clinic pathological and survival parameters in HER-2 positive breast cancer patients?
    (2018) MUNDIM, F.; FRANCO, A.; INFANTE, K.; NETO, J.; BRENTANI, M. M.; FACINA, G.; WAITZBERG, A.
  • conferenceObject
    Claudin 4 and 7 Expression Is Not Correlated to Triple Negative Phenotype in Invasive NOS Breast Carcinomas: A Wide Series Assessed by Immunohistochemistry
    (2014) LOGULLO, A. F.; STIEPCICH, M. A.; NONOGAKI, S.; MALAGOLI, R.; BRENTANI, M. M.; PASINI, F. S.; SOARES, F. A.
  • article 18 Citação(ões) na Scopus
    Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma
    (2011) LOGULLO, Angela Flavia; STIEPCICH, Monica Maria Agata; OSORIO, Cintia Aparecida Bueno de Toledo; NONOGAKI, Sueli; PASINI, Fatima Solange; ROCHA, Rafael Malagoli; SOARES, Fernando Augusto; BRENTANI, Maria M.
    Aims: Fos-related antigen 1 (Fra-1) is a member of the activator protein 1 (AP-1) transcription factor family. Our objective was to evaluate the role of Fra-1 expression in breast carcinoma progression and prognosis. Methods and results: Fra-1 expression was investigated by immunohistochemistry in two tissue microarrays containing, respectively, 85 ductal carcinoma in situ (DCIS) and 771 invasive ductal carcinoma (IDC) samples. Staining was observed in the nucleus and cytoplasm of the carcinomas, but only nuclear staining was considered to be positive. Fibroblasts associated with IDC were also Fra-1-positive. The frequency of Fra-1 positivity in IDC (22.8%) was lower than that in DCIS (42.2%). No association was found between Fra-1 and clinico-pathological variables in DCIS. In IDC, Fra-1 expression correlated with aggressive phenotype markers, including: high grade, oestrogen receptor negativity and human epidermal growth factor receptor 2 (HER-2) positivity (P = 0.001, 0.015 and 0.004, respectively), and marginally with the presence of metastasis (P = 0.07). Fra-1 was more frequently positive in basal-like (34%) and in HER-2-positive (38.5%) subtypes than in luminal subtypes. Fra-1 presence did not correlate with survival. Conclusions: A high frequency of Fra-1 in DCIS tumours may be associated with early events in breast carcinogenesis. Although Fra-1 expression correlated with features of a more aggressive phenotype in IDC, no relationship with overall survival was found.
  • article 12 Citação(ões) na Scopus
    Breast Carcinoma-associated Fibroblasts Share Similar Biomarker Profiles in Matched Lymph Node Metastasis
    (2016) MUNDIM, Fiorita G. L.; PASINI, Fatima S.; NONOGAKI, Suely; ROCHA, Rafael M.; SOARES, Fernando A.; BRENTANI, Maria M.; LOGULLO, Angela F.
    This study sought to understand the role of breast carcinoma-associated fibroblasts in the progression of cancer cells into lymph nodes. We compared fibroblasts of primary tumors and matched the involved lymph nodes to select fibroblast activation markers, namely -smooth muscle actin (-SMA), S100A4, and vimentin, as well as to determine the frequency of transforming growth factor 1, a pleiotropic cytokine that induces the differentiation of fibroblasts to myofibroblasts, and its downstream effectors: CXCR4 and p-AKT. We disposed samples of 80 primary invasive ductal carcinomas and matched the involved lymph nodes from 43 cases into 3 tissue microarrays, and analyzed stromal and tumor epithelial cells separately by immunohistochemistry. Control uninvolved lymph nodes were analyzed by whole-tissue sections. Cancer-associated fibroblast in lymph nodes with macrometastasis expressed similar profiles of vimentin, -SMA, and S100A4 as those found in primary tumors. Cancer-associated fibroblast were uniformly estrogen receptor, progesterone receptor, HER-2, Ki-67, and p53 negative, but expressions of transforming growth factor 1 (TGF1), CXCR4, and p-AKT staining (62.3%, 52.4%, 65%, respectively) were equivalent between primary and lymph node metastasis (LNM) fibroblasts. A significant coexpression of TGF1 with p-AKT and CXCR4 in LNMs suggested the involvement of these proteins with TGF1 signaling. These biomarkers, including -SMA and S100A4, were negative in fibroblasts of cancer-free lymph nodes, with the exception of vimentin. Our finding that expressions of biological markers were similar in fibroblasts of the primary tumors and in matched LNMs, but were absent in cancer-free lymph nodes, supports the assumption that the lymph node stroma mimics the microenvironment observed in primary tumors.